Two divisions of Serologicals and Pittsburgh-based biotech Cellumen plan to co-develop and sell a cytotoxicity profiling panel and services for use in pharmaceutical drug discovery, the firms said this week.

For reagent provider Serologicals, the partnership marks the biggest step it has taken to date in the direction of cell-based assays for drug discovery; specifically, it expects the deal to help it gain a foothold in the high-content cellular-assay market, an area in which it has limited experience.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.